內(nèi)脂素(VF)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Visfatin (VF)
Nampt; NAmPRTase; PBEF; PBEF1; Pre-B-Cell Colony Enhancing Factor; Nicotinamide Phosphoribosyltransferase
- 編號(hào)CEA638Ra
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法競(jìng)爭(zhēng)抑制
- 反應(yīng)時(shí)長(zhǎng)2h
- 檢測(cè)范圍1.23-100ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.47ng/mL.
- 樣本類型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 3032 ¥ 4332 ¥ 19494 ¥ 36822 ¥ 303240
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)內(nèi)脂素(VF)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的內(nèi)脂素(VF)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 96-103 | 101 |
| EDTA plasma(n=5) | 87-101 | 95 |
| heparin plasma(n=5) | 80-97 | 94 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的內(nèi)脂素(VF)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中內(nèi)脂素(VF)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 81-98% | 88-98% | 97-105% | 90-99% |
| EDTA plasma(n=5) | 85-101% | 91-98% | 79-104% | 82-104% |
| heparin plasma(n=5) | 78-97% | 90-98% | 83-101% | 96-105% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）50µL，
加入50µL檢測(cè)液A(臨用前配制);
37°C溫育1小時(shí)。
3. 洗板3次；
4. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
5. 洗板5次；
6. 加TMB底物90µL，37°C孵育10-20分鐘；
7. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
本試劑盒應(yīng)用競(jìng)爭(zhēng)抑制酶聯(lián)免疫分析法測(cè)定標(biāo)本中待測(cè)物質(zhì)水平。將內(nèi)脂素(VF)單克隆抗體包被微孔板，制成固相載體，往包被抗體的微孔中同時(shí)加入生物素標(biāo)記的抗原和待測(cè)抗原(標(biāo)準(zhǔn)品或樣本)，待測(cè)抗原與生物素標(biāo)記抗原對(duì)特異性抗體進(jìn)行競(jìng)爭(zhēng)結(jié)合。溫育后經(jīng)洗滌去掉未結(jié)合物，然后加入HRP標(biāo)記的親和素，經(jīng)過(guò)溫育和徹底洗滌后加入底物TMB顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。待測(cè)標(biāo)本濃度越高，標(biāo)記抗原和抗體的結(jié)合就越受到抑制，顯色愈淺。顯色的深淺與酶量呈正相關(guān)，而與樣品中待測(cè)物質(zhì)含量呈負(fù)相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度（O.D.值），計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA638Ra01 | 內(nèi)脂素(VF)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA638Ra01 | 內(nèi)脂素(VF)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA638Ra71 | 內(nèi)脂素(VF)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| LAA638Ra81 | 內(nèi)脂素(VF)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| MAA638Ra21 | 內(nèi)脂素(VF)單克隆抗體 | WB; IHC; ICC; IP. |
| SEA638Ra | 內(nèi)脂素(VF)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| CEA638Ra | 內(nèi)脂素(VF)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA638Ra | 內(nèi)脂素(VF)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| CGA638Ra01 | 內(nèi)脂素(VF)cDNA | PCR、蛋白表達(dá)等 |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Brazilian Journal of Biomoricity | EFFECT OF 8 WEEKS ENDURANCE TRAINING ON PLASMA VISFATIN IN MIDDLE-AGED MEN [Brjb: source] |
| Diabetes Research and Clinical Practice | The relationship between visfatin and HOMA-IR in hypertensive patients, and the effect of antihypertensive drugs on visfatin and HOMA-IR in hypertensive patients with insulin resistance [ScienceDirect: S0168822711002956] |
| J Physiol Pharmacol. | Early-effect of bariatric surgery (Scopinaro method) on intestinal hormones and adipokines in insulin resistant Wistar rat. [Pubmed: 24304571] |
| Endocr J. | CTRP3 modulates the expression and secretion of adipokines in 3T3-L1 adipocytes [Pubmed:25168658] |
| Exp Ther Med. | Plasma visfatin levels and mRNA expression of visfatin in peripheral blood mononuclear cells and peripheral blood monocyte-derived macrophages from normal weight females with polycystic ovary syndrome [Pubmed:Pmc3991522] |
| Eur J Cancer Prev. | Visfatin derived from ascites promotes ovarian cancer cell migration through Rho/ROCK signaling-mediated actin polymerization. [Pubmed:25055182] |
| Genome | Visfatin ?948G/T?and resistin ?420C/Gpolymorphisms in Egyptian type 2 diabetic patients with and without cardiovascular diseases [Nrcresearchpress:Source] |
| PLOS ONE | Antidiabetic Effect of Galantamine: Novel Effect for a Known Centrally Acting Drug [PubMed: 26262991] |
| Alcoholism and Drug Addiction | Changes in concentration of visfatin during four weeks of inpatient treatment of alcohol dependent males [Science: Article] |
| Cytokine | Variation in blood levels of hormones in obese patients following weight reduction induced by endoscopic and surgical bariatric therapies [PubMed: 26539806] |
| Genome | Genetic Variations in Visfatin and Resistin Genes in Egyptian Type 2 Diabetic Patients With and Without Complications [PubMed: 25120107] |
| Acta Histochemica | Favorable outcomes of hydroxychloroquine in insulin resistance may be accomplished by adjustment of the endothelial dysfunction as well as the skewed balance of adipokines [science:S0065128116301234] |
| Endocrine, Metabolic & Immune Disorders-Drug Targets | Changes in Serum Nampt Levels and Its Significances in Diabetic Nephropathy Patients-The Potential Role of Nampt in T2DM with Diabetic Nephropathy. [pubmed:28699485] |
| Endocrine?Connections | Post-chemotherapy serum anti-müllerian hormone level predicts ovarian function recovery [Pubmed:30012648] |
| Bioscience Reports | Effect of maternal hypothyroidism during pregnancy on insulin resistance, lipid accumulation and mitochondrial dysfunction in skeletal muscle of fetal rats [Pubmed:29784871] |
| Contraception | Hyperinsulinemic-euglycemic clamp over the first year of use of depot-medroxyprogesterone acetate as a contraceptive [Pubmed:29665358] |
| Cranio?-?Journal?of?Craniomandibular?Practice | Analysis of synovial fluid visfatin level in temporomandibular joint disorders [Pubmed:29385907] |
| Nutrire | Resistin and visfatin concentrations are related to central obesity and inflammation in Brazilian children [10.1186:s41110-018-0060-7] |
| DNA?and?Cell?Biology | Transcriptional Regulation of?NAMPT?Gene by Glycogen Synthase Kinase 3β in Goat Adipocytes [Pubmed: 30615481] |
| Jundishapur?Journal of?Chronic?Disease?Care | The Effect of 8 Weeks Aquatic Exercise Program on Plasma Visfatin Level and Some Blood Factors in Obese Men [] |
| Biomarkers in Heart Failure and Associated Diseases | Adipokines as Biomarkers in Health and Disease [] |
| Journal of Translational Medicine | Plasma concentration and expression of adipokines in epicardial and subcutaneous adipose tissue are associated with impaired left ventricular filling pattern [Pubmed: 31533725] |
| clinical neurology and neurosurgery | Relationsh?p of spontaneous subarachnoid haemorrhage and cerebral aneurysm to serum Visfatin and Nesfatin-1 levels [Pubmed: 32311618] |
| The Horizon of Medical Sciences | Effects of 10-Week Concurrent Training on Insulin Resistance and the Serum Levels of Vaspin and Visfatin in Overweight Females [] |
| EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY | Different Ratios of Corn and Coconut Oil Blends in High?\Fat Diets Influence Fat Deposition without Altering Metabolic Biomarkers in Male Rats [] |
